Cargando…

Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature

PURPOSE: To evaluate the role of sentinel lymph node (SLN) biopsy in patients with conjuctival melanoma (CjM). STUDY DESIGN: Retrospective observational cohort study and literature review. SUBJECTS: Slovenian patients with CjM are included in the study. METHODS: Prospectively collected data of CjM p...

Descripción completa

Detalles Bibliográficos
Autores principales: Peric, Barbara, Leiler, Spela, Hawlina, Gregor, Jancar, Boris, Snoj, Marko, Perhavec, Andraz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512233/
https://www.ncbi.nlm.nih.gov/pubmed/34633246
http://dx.doi.org/10.1177/10732748211042116
_version_ 1784582942059659264
author Peric, Barbara
Leiler, Spela
Hawlina, Gregor
Jancar, Boris
Snoj, Marko
Perhavec, Andraz
author_facet Peric, Barbara
Leiler, Spela
Hawlina, Gregor
Jancar, Boris
Snoj, Marko
Perhavec, Andraz
author_sort Peric, Barbara
collection PubMed
description PURPOSE: To evaluate the role of sentinel lymph node (SLN) biopsy in patients with conjuctival melanoma (CjM). STUDY DESIGN: Retrospective observational cohort study and literature review. SUBJECTS: Slovenian patients with CjM are included in the study. METHODS: Prospectively collected data of CjM patients treated from June 2005 to December 2016 were retrospectively analyzed. MAIN OUTCOME MEASURES: The numbers of SLN biopsy procedures, positive and false positive SLN, and local and regional relapses have been described together with overall survival. RESULTS: From June 2005 until December 2016, 24 patients with CjM were treated. The median follow-up time was 65.3 months. The mean Breslow thickness was 1.5 mm (sd = 1.8 mm), and ulceration was present in 29% of cases. Altogether, 14/24 (58%) SLN biopsy procedures were performed. SLN was positive in 2/14 (14%) cases. The estimated 5-year overall survival (OS) of the group was 72.5%, with a median survival of 151 months (95% CI 77–224). From January 2013 to January 2020, five (5/140, 3%) authors reported results comparable to our study. CONCLUSION: Our results confirm that CjM is a rare disease with approximately 14% of positive SLN. At the moment, there are no firm conclusions regarding who would benefit most from SLN biopsy or whether or not CLND should be offered. Data from literature emphasize the need for consistent and uniform staging and future multicentric studies.
format Online
Article
Text
id pubmed-8512233
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85122332021-10-14 Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature Peric, Barbara Leiler, Spela Hawlina, Gregor Jancar, Boris Snoj, Marko Perhavec, Andraz Cancer Control Original Research Article PURPOSE: To evaluate the role of sentinel lymph node (SLN) biopsy in patients with conjuctival melanoma (CjM). STUDY DESIGN: Retrospective observational cohort study and literature review. SUBJECTS: Slovenian patients with CjM are included in the study. METHODS: Prospectively collected data of CjM patients treated from June 2005 to December 2016 were retrospectively analyzed. MAIN OUTCOME MEASURES: The numbers of SLN biopsy procedures, positive and false positive SLN, and local and regional relapses have been described together with overall survival. RESULTS: From June 2005 until December 2016, 24 patients with CjM were treated. The median follow-up time was 65.3 months. The mean Breslow thickness was 1.5 mm (sd = 1.8 mm), and ulceration was present in 29% of cases. Altogether, 14/24 (58%) SLN biopsy procedures were performed. SLN was positive in 2/14 (14%) cases. The estimated 5-year overall survival (OS) of the group was 72.5%, with a median survival of 151 months (95% CI 77–224). From January 2013 to January 2020, five (5/140, 3%) authors reported results comparable to our study. CONCLUSION: Our results confirm that CjM is a rare disease with approximately 14% of positive SLN. At the moment, there are no firm conclusions regarding who would benefit most from SLN biopsy or whether or not CLND should be offered. Data from literature emphasize the need for consistent and uniform staging and future multicentric studies. SAGE Publications 2021-10-11 /pmc/articles/PMC8512233/ /pubmed/34633246 http://dx.doi.org/10.1177/10732748211042116 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Peric, Barbara
Leiler, Spela
Hawlina, Gregor
Jancar, Boris
Snoj, Marko
Perhavec, Andraz
Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature
title Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature
title_full Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature
title_fullStr Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature
title_full_unstemmed Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature
title_short Sentinel Node Biopsy for Conjunctival Melanoma; Single Centre Experience and Review of Current Literature
title_sort sentinel node biopsy for conjunctival melanoma; single centre experience and review of current literature
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512233/
https://www.ncbi.nlm.nih.gov/pubmed/34633246
http://dx.doi.org/10.1177/10732748211042116
work_keys_str_mv AT pericbarbara sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature
AT leilerspela sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature
AT hawlinagregor sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature
AT jancarboris sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature
AT snojmarko sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature
AT perhavecandraz sentinelnodebiopsyforconjunctivalmelanomasinglecentreexperienceandreviewofcurrentliterature